Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $57,360 | $120,964 | $156,584 | $350,622 |
| - Cash | $150,572 | $77,111 | $77,741 | $60,412 |
| + Debt | $10,020 | $10,950 | $11,888 | $12,808 |
| Enterprise Value | -$83,192 | $54,803 | $90,731 | $303,018 |
| Revenue | $82,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $82,000 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | $50,781 | -$30,910 | -$33,154 | -$36,872 |
| % Margin | 61.9% | – | – | – |
| Net Income | $50,959 | -$30,998 | -$33,513 | -$37,367 |
| % Margin | 62.1% | – | – | – |
| EPS Diluted | 0.99 | -0.6 | -0.65 | -0.72 |
| % Growth | 265% | 7.7% | 9.7% | – |
| Operating Cash Flow | $59,234 | -$31,540 | -$23,405 | -$33,166 |
| Capital Expenditures | -$223 | -$240 | -$349 | -$107 |
| Free Cash Flow | $59,011 | -$31,780 | -$23,754 | -$33,273 |